<DOC>
	<DOCNO>NCT01461499</DOCNO>
	<brief_summary>The purpose study compare effect direct renin inhibitor ( DRI ) , aliskiren , urinary albumin excretion hypertensive patient type 2 diabetes strict blood pressure control angiotensin receptor blocker ( ARB ) .</brief_summary>
	<brief_title>Shiga Microalbuminuria Reduction Trial-2</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Segment : outpatient Hypertension : take antihypertensive treatment indicate mean sit SBP/DBP than130/80 mmHg Type 2 diabetes : diagnose ADA criterion antidiabetic drug treatment Microalbuminuria : 10 &lt; &lt; 300 mg/gCr Informed consent : patient understand well study base voluntary give write consent Sever hypertension ( 180/110 mmHg ) , malignant hypertension secondary hypertension Type 1 diabetes Patients whose investigator regard difficult comply study protocol reference package insert aliskiren Patients history operation gastrointestinal tract surgery , anamnestic concurrent gastrointestinal disorder , may interfere drug absorption Serum potassium &gt; 5.6 mEq/L ( hyperkalemia ) Urinary microalbmiurin &lt; 10 &gt; 300 mg/gCr Patients participate another clinical study within three month</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Albuminuria</keyword>
	<keyword>Direct renin inhibitor</keyword>
	<keyword>Angiotensin receptor blocker</keyword>
	<keyword>Type 2 diabetes</keyword>
</DOC>